Core Insights - RenovoRx generated $1.1 million in revenue from RenovoCath in its first full year of commercialization, indicating strong initial adoption by physicians and demand in active cancer centers [2][3][15] - The company has established a solid commercial infrastructure and plans to scale operations in 2026, focusing on high-volume cancer centers [2][10] - The ongoing Phase III TIGeR-PaC trial is on track for full enrollment by mid-2026, with final data expected in 2027 [1][7][8] Financial Performance - For the year ended December 31, 2025, RenovoRx reported revenue of $1.1 million, a significant increase from $43,000 in 2024 [15][25] - The net loss for 2025 was approximately $11.2 million, compared to $8.8 million in the previous year [19][25] - Cash and cash equivalents were approximately $7.0 million as of December 31, 2025, and increased to $13 million following a private placement in March 2026 [16][14] Commercialization and Market Strategy - As of early 2026, 12 cancer centers are actively using RenovoCath, with an additional 21 centers evaluating or preparing for activation, tripling the near-term pipeline compared to early 2025 [2][5] - The company estimates a total addressable market (TAM) of approximately $400 million for RenovoCath as a stand-alone device, with potential for multi-billion-dollar expansion into additional solid tumor indications [6][29] - The company is observing repeat ordering patterns and increased procedural utilization, reinforcing confidence in physician satisfaction and the potential for recurring revenue [5][4] Clinical Development - The TIGeR-PaC trial is evaluating intra-arterial delivery of gemcitabine via RenovoCath for locally advanced pancreatic cancer, with 104 patients randomized as of March 24, 2026 [7][8] - The trial has reached a key milestone with the completion of a second interim analysis, and the independent Data Monitoring Committee recommended continuing the study without modification [8][9] - The company aims to transition 17 cancer centers involved in the TIGeR-PaC trial to commercial customers for RenovoCath in the second half of 2026 [2][7] Leadership and Advisory Board - In February 2026, RenovoRx strengthened its executive leadership team with the appointment of Mark Voll as Chief Financial Officer, bringing over 30 years of financial leadership experience [11] - The company established the RenovoCath Medical Advisory Board to provide strategic clinical guidance, comprising leading interventional oncology experts [12]

Core Insights - RenovoRx has surpassed 100 randomized patients in its Phase III TIGeR-PaC clinical trial and is on track to complete enrollment in the first half of 2026, with final data expected in 2027 [1][2][3] Company Overview - RenovoRx, Inc. is a life sciences company focused on developing targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device [6] - The company’s TAMP™ therapy platform aims to deliver therapeutic agents directly to tumor sites while minimizing toxicities associated with systemic intravenous therapy [6] Clinical Trial Progress - The TIGeR-PaC trial requires a total of 114 randomized patients and 86 events (deaths) for final analysis; as of March 24, 2026, 104 patients have been randomized and 72 events have occurred [3] - Interim analyses conducted at the 26th and 52nd events recommended continuation of the trial based on data reviews by the independent data monitoring committee [4] Product Development - The intra-arterial gemcitabine delivered via RenovoCath, known as IAG, is being evaluated in the TIGeR-PaC trial for its potential to treat locally advanced pancreatic cancer [2][9] - RenovoCath has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon FDA approval [10] Commercialization Efforts - RenovoRx is in the early stages of commercializing its TAMP technology and RenovoCath as a stand-alone device, having received its first commercial purchase orders in December 2024 [7][8] - Approximately $900,000 in revenues were generated from RenovoCath sales in the first nine months of 2025, with several customers placing repeat orders [8]

Core Viewpoint - RenovoRx, Inc. has successfully closed an oversubscribed private placement, raising approximately $10 million to support its business plan and clinical milestones, particularly for its FDA-cleared drug-delivery device, RenovoCath [1][3][6] Financing Details - The private placement was led by both new and existing institutional investors, including Transcend Partners, LLC and AIGH Capital Management LLC, with participation from RenovoRx's senior management and Board of Directors [2] - A total of 10,638,790 shares of common stock were issued at a price of $0.938 per share, along with revenue milestone warrants for an additional 5,319,392 shares [4] - The exercise price for the revenue milestone warrants is set at $1.751, representing a 100% premium to the offering price [5] Business Strategy and Milestones - The proceeds from the financing will be utilized to accelerate the market adoption of RenovoCath and advance clinical development, with a focus on achieving full enrollment in the pivotal Phase III trial by mid-2026 [3][7] - The company anticipates significant growth in commercial revenues, which will help reduce cash burn and support the goal of cash-flow breakeven operations [3] Leadership and Team - Mark Voll has been appointed as Chief Financial Officer, bringing a strong track record of scaling public companies [3] - The company has established a core, nimble, and capital-efficient commercial team for RenovoCath [3] Clinical Development - RenovoRx is nearing completion of enrollment in its pivotal Phase III TIGeR-PaC clinical trial, with results expected in 2027 [3][7] - The trial involves 16 additional commercial centers that are already trained on RenovoCath procedures and have begun purchasing devices [3] Product Overview - RenovoCath is designed for targeted delivery of fluids to specific sites in the peripheral vascular system and is indicated for temporary vessel occlusion [10][11] - The company is also evaluating a novel drug-device combination product candidate, intra-arterial gemcitabine delivered via RenovoCath, in the ongoing Phase III trial [13][14]

Core Viewpoint - RenovoRx, Inc. is set to announce its fourth quarter and full year 2025 financial results and business highlights on March 30, 2026, showcasing its progress in oncology therapies and the commercialization of its FDA-cleared drug-delivery device, RenovoCath [1][4]. Group 1: Financial Results and Conference Call - The conference call will take place on March 30, 2026, at 4:30 p.m. ET, where management will discuss financial results and business highlights [1][4]. - A recording of the call will be available on the Investor Relations website, with a dial-in replay accessible until April 13, 2026 [4]. Group 2: Clinical Pipeline and Product Development - Management will provide updates on the clinical pipeline, particularly the Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, which is on track for enrollment completion in the first half of 2026, with final data expected in 2027 [3]. - The company is focusing on generating new data through post-marketing registry studies and supporting investigator-initiated trials (IIT) in pancreatic cancer, which are designed to be cost-neutral and provide meaningful data for the TAMP™ therapy platform [3]. Group 3: Commercialization Efforts - RenovoRx is in the early stages of commercializing its TAMP technology and RenovoCath, having received its first commercial purchase orders in December 2024, generating approximately $900,000 in revenue from RenovoCath sales in the first nine months of 2025 [6]. - The company is expanding its customer base, including high-volume National Cancer Institute-designated centers, and is exploring further revenue-generating activities [6]. Group 4: Product Candidates and Regulatory Status - RenovoRx is evaluating its intra-arterial gemcitabine product candidate delivered via RenovoCath in the ongoing Phase III TIGeR-PaC trial, which is regulated under a U.S. investigational new drug application [7]. - The IAG combination product candidate has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [8].

Core Viewpoint - RenovoRx, Inc. has successfully executed an oversubscribed private placement expected to generate approximately $10 million in gross proceeds, aimed at accelerating its commercialization efforts and advancing clinical trials for its innovative oncology therapies [1][3][6] Financing Details - The financing is led by prominent life-science institutional investors, with participation from the company's senior management and board members [2] - The private placement will involve the issuance of approximately 10,638,869 shares of common stock at a purchase price of $0.938 per share, along with milestone-based warrants for an additional 5,319,434 shares [4][5] Use of Proceeds - Proceeds from the financing are intended to support RenovoRx's commercialization of RenovoCath and to advance the pivotal Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer, targeting full enrollment by mid-2026 [3][12] - The company aims to achieve cash-flow breakeven operations while reducing cash burn and increasing revenue [3] Warrant Details - The milestone warrants have an exercise price of $1.751 per share, representing a 100% premium to the common stock offering price, and are exercisable immediately [5] - The warrants will expire either 30 days after the company announces achieving $1.5 million in gross product revenue or on March 30, 2029 [5] Company Overview - RenovoRx is focused on developing targeted oncology therapies and commercializing RenovoCath, a patented FDA-cleared drug-delivery device designed for localized treatment [11][12] - The company has generated approximately $900,000 in revenue from RenovoCath sales in the first nine months of 2025, with repeat orders from several customers [12]

Core Viewpoint - Citius Oncology, Inc. has successfully launched LYMPHIR, generating $3.9 million in revenue for the first fiscal quarter of 2026, marking a significant transition from a development-stage organization to a commercial oncology company [1]. Business Highlights and Subsequent Developments - The company is focused on accelerating physician adoption and expanding patient access to LYMPHIR, with initial distributor sales completed nationwide [1]. - Citius Oncology is preparing to expand its field presence to support a concentrated prescriber base in the rare cancer setting, utilizing an AI-enabled commercial platform for market penetration [1]. - The company is exploring strategic opportunities to enhance long-term shareholder value while managing capital effectively [1]. Financial Highlights for First Quarter 2026 - The net loss for the quarter was $5.5 million, or $(0.06) per share, an improvement from a net loss of $6.7 million, or $(0.09) per share, in the prior-year period [1]. - Stock-based compensation expense increased to $4.0 million, primarily due to equity grants, compared to $1.8 million in the previous year [1]. - General and administrative expenses decreased to $2.9 million from $3.3 million, while research and development expenses were reduced to $1.0 million from $1.3 million [1]. - The company completed a registered offering in December 2025, generating net proceeds of approximately $15.1 million, and reported cash and cash equivalents of $7.3 million as of December 31, 2025 [1]. Market Opportunity - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies [1]. - Citius Oncology holds robust intellectual property protections, including orphan drug designation and pending patents for immuno-oncology use, which support its competitive positioning [1].

Core Insights - RenovoRx has established a Medical Advisory Board (MAB) to enhance its TAMP™ therapy platform, focusing on clinical indications with high unmet medical needs [1][2][5] Group 1: Medical Advisory Board Formation - The MAB consists of leading US interventional radiology experts who will provide strategic clinical insights to advance the TAMP therapy platform [2][3] - The MAB will complement the existing Scientific Advisory Board, which focuses on scientific research and clinical program strategy [2] Group 2: Clinical and Market Strategy - The MAB will support ongoing clinical and market strategies and provide insights into potential investigator-initiated trials, which are designed to broaden the application of the TAMP platform [3] - Current trials supported by RenovoRx include studies on borderline resectable and metastatic pancreatic cancer, with potential for expanding targeted indications [3] Group 3: Feedback and Market Introduction - The MAB will also provide feedback to the sales and marketing team as they work to bring RenovoCath to market as a standalone device within its FDA-cleared indications [4] Group 4: RenovoCath Overview - RenovoCath is an FDA-cleared drug-delivery device intended for targeted therapeutic delivery across the arterial wall near tumor sites, aiming to minimize toxicities compared to systemic intravenous therapy [12][13] - The device is also indicated for temporary vessel occlusion in various applications, including arteriography and chemotherapeutic drug infusion [12] Group 5: Commercialization Efforts - RenovoRx is in the early stages of commercializing its TAMP technology and has received its first commercial purchase orders for RenovoCath devices, generating approximately $900,000 in revenue for the first nine months of 2025 [14] - The company is actively exploring further revenue-generating activities to meet anticipated demand [14] Group 6: Ongoing Clinical Trials - RenovoRx is evaluating its intra-arterial gemcitabine product candidate (IAG) in the ongoing Phase III TIGeR-PaC trial, which utilizes the RenovoCath device [15][16] - IAG has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [17]

Core Viewpoint - RenovoRx has appointed Mark Voll as Chief Financial Officer to enhance its leadership team and support the commercialization of its RenovoCath drug-delivery device, marking a significant transition from a clinical stage to a commercial company [1][4]. Group 1: Appointment and Leadership - Mark Voll brings over 30 years of financial leadership experience, having successfully guided high-growth public companies through commercial development [2]. - Voll's role will focus on stockholder communications, budgeting, strategic planning, and finance, which are crucial as RenovoRx commercializes RenovoCath and advances its Phase III TIGeR-PaC clinical trial [3][4]. - CEO Shaun Bagai expressed confidence in Voll's ability to drive sustained commercial execution during this pivotal time for the company [4]. Group 2: Company Overview and Product Information - RenovoRx is a life sciences company focused on developing targeted oncology therapies and commercializing RenovoCath, an FDA-cleared drug-delivery device designed for targeted therapeutic delivery [7]. - RenovoCath is intended for isolating blood flow and delivering fluids to specific sites in the peripheral vascular system, with applications including arteriography and chemotherapeutic drug infusion [6]. - The company has begun commercializing the TAMP therapy platform and RenovoCath, generating approximately $900,000 in revenue from sales in the first nine months of 2025 [8]. Group 3: Clinical Trials and Future Prospects - RenovoRx is evaluating a novel drug-device combination candidate, IAG, in the ongoing Phase III TIGeR-PaC trial, which utilizes the RenovoCath device [9][10]. - IAG has received Orphan Drug Designation for pancreatic and bile duct cancers, providing seven years of market exclusivity upon FDA approval [10].

Core Insights - RenovoRx, Inc. is advancing its innovative targeted oncology therapies through the RenovoCath device, which has received FDA clearance for drug delivery [1][7] - New clinical data will be presented at the 2026 Society of Interventional Oncology Annual Scientific Meeting, focusing on optimizing drug delivery in solid tumors using the TAMP therapy platform [1][2] Clinical Study Findings - The study titled "Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro-Perfusion to Optimize Drug Delivery in Solid Tumors" aims to simplify intra-arterial pressure measurement during TAMP procedures [2][4] - Real-time pressure measurements provide insights into the mechanics of TAMP procedures, potentially enhancing drug delivery effectiveness [3][4] - The study demonstrates that an external pressure transducer can reliably measure intra-arterial pressure, correlating well with intravascular pressure wire measurements [3] Presentation Details - The clinical data will be presented on February 6, 2026, at 5:45-6:00 PM ET, with the abstract number 303 [4] Company Overview - RenovoRx is focused on developing targeted therapies for high unmet medical needs, utilizing the TAMP therapy platform to minimize toxicities compared to systemic therapies [7] - The company is in the early stages of commercializing the RenovoCath device, having generated approximately $900,000 in revenue from sales in the first nine months of 2025 [8] Product Development - RenovoRx is evaluating a novel drug-device combination candidate, IAG, which involves intra-arterial delivery of gemcitabine via RenovoCath, currently in Phase III trials [9][10] - IAG has received Orphan Drug Designation for pancreatic and bile duct cancers, granting seven years of market exclusivity upon FDA approval [10]

Core Insights - RenovoRx, Inc. announced the acceptance of its abstract submission for the 2026 Society of Interventional Oncology Annual Scientific Meeting, highlighting its innovative targeted oncology therapies and the RenovoCath drug-delivery device [1][6] Group 1: Clinical Study Presentation - The clinical data abstract titled "Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro-Perfusion to Optimize Drug Delivery in Solid Tumors" will be presented by researchers including Dr. Christopher Laing [2] - The study aims to validate a real-time method for intra-arterial pressure monitoring during TAMP procedures using the RenovoCath device, potentially optimizing chemotherapy delivery in challenging tumors [4] Group 2: RenovoCath Overview - RenovoCath is FDA-cleared for isolating blood flow and delivering fluids to specific sites in the peripheral vascular system, with applications in arteriography, preoperative occlusion, and chemotherapeutic drug infusion [5][7] - The device is part of RenovoRx's TAMP therapy platform, designed to enhance targeted therapeutic delivery while minimizing toxicities compared to systemic intravenous therapy [7] Group 3: Commercialization and Financials - RenovoRx is in the early stages of commercializing its TAMP technology and has received its first commercial purchase orders for RenovoCath, generating approximately $900,000 in revenue from sales in the first nine months of 2025 [8] - The company is expanding its customer base, including high-volume National Cancer Institute-designated centers, and is exploring further revenue-generating activities [8] Group 4: Ongoing Clinical Trials - RenovoRx is evaluating its intra-arterial gemcitabine product candidate (IAG) in the Phase III TIGeR-PaC trial, which utilizes the RenovoCath device [9] - IAG has received Orphan Drug Designation for pancreatic and bile duct cancers, providing seven years of market exclusivity upon FDA approval [10]